 |
Market Cap | 37.13M | EPS (ttm) | 1.04 |
P/E | 7.58 | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | 1.24 | EPS Q/Q | -51.69% |
Dividend | - | Sales Q/Q | -5925.72% |
Insider Own | 57.67% | Inst Own | 1.34% |
Insider Trans | 0.12% | Inst Trans | - |
Short Float | 0.55% | Earnings | - |
Analyst Recom | 1.00 | Target Price | 23.00 |
Avg Volume | 2.25K | 52W Range | 7.11 - 13.13 |
|
|
|
Daxor Corp. is a biotechnology company which develops and manufactures the BVA-100 blood volume analyzer, an instrument that measures human blood volume. Its IDANT division provides autologous blood storage and andrology services, such as semen analysis, sperm washing, and general lab testing. The company was founded by Joseph Feldschuh in 1970 and is headquartered in Oak Ridge, TN. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Feldschuh Michael Richard | Chief Executive Officer | Dec 01 | Buy | 7.80 | 800 | 6,240 | 162,492 | Dec 01 08:58 PM | Michel Robert J | Chief Financial Officer | Dec 01 | Buy | 7.75 | 180 | 1,395 | 10,430 | Dec 01 09:00 PM | Michel Robert J | Chief Financial Officer | Nov 24 | Buy | 7.94 | 500 | 3,970 | 10,250 | Nov 27 06:03 AM | Feldschuh Michael Richard | CHIEF EXECUTIVE OFFICER | Nov 10 | Buy | 7.83 | 1,001 | 7,838 | 161,608 | Nov 13 06:33 AM | Feldschuh Michael Richard | CHIEF EXECUTIVE OFFICER | Nov 09 | Buy | 7.85 | 401 | 3,148 | 160,607 | Nov 13 06:33 AM |
|
|
 |
 |
Market Cap | 187.82M | EPS (ttm) | -5.65 |
P/E | - | EPS this Y | 34.35% |
Forward P/E | - | EPS next Y | 27.76% |
PEG | - | EPS past 5Y | -110.36% |
P/S | 50.90 | EPS next 5Y | 9.80% |
P/B | 2.63 | EPS Q/Q | 44.68% |
Dividend | - | Sales Q/Q | - |
Insider Own | 18.13% | Inst Own | 70.24% |
Insider Trans | 0.46% | Inst Trans | 13.36% |
Short Float | 22.67% | Earnings | Nov 03/b |
Analyst Recom | 1.86 | Target Price | 15.86 |
Avg Volume | 2.39M | 52W Range | 1.77 - 18.04 |
|
|
|
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Watanabe Todd Franklin | See Remarks | Dec 01 | Option Exercise | 1.68 | 59,525 | 100,038 | 513,682 | Dec 01 08:51 PM | Matsuda Masaru | See Remark | Nov 21 | Sale | 1.98 | 1,850 | 3,661 | 46,634 | Nov 21 05:47 PM | Frazier Life Sciences VIII, L. | 10% Owner | Oct 24 | Buy | 2.50 | 80,000 | 200,000 | 8,764,232 | Oct 26 04:09 PM | Burnett Patrick | See Remarks | Aug 21 | Sale | 7.04 | 1,605 | 11,302 | 58,357 | Aug 22 12:24 PM | Watanabe Todd Franklin | See Remarks | May 31 | Buy | 6.38 | 1,463 | 9,334 | 515,145 | Dec 01 08:51 PM |
|
|
 |
 |
Market Cap | 34.37M | EPS (ttm) | -0.05 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | 1.26 | EPS next 5Y | - |
P/B | 1.19 | EPS Q/Q | -1270.21% |
Dividend | - | Sales Q/Q | -23.21% |
Insider Own | 18.54% | Inst Own | 27.84% |
Insider Trans | 29.62% | Inst Trans | -0.75% |
Short Float | 0.60% | Earnings | Nov 14/a |
Analyst Recom | 1.00 | Target Price | 16.00 |
Avg Volume | 15.73K | 52W Range | 3.93 - 15.82 |
|
|
|
CVD Equipment Corp. engages in the design, development, and manufacture of chemical vapor deposition, gas control, and other state-of-the-art equipment and process solutions. It operates through the following segments: Chemical Vapor Deposition (CVD), Stainless Design Concepts (SDC), CVD Materials, and Corporate. The Chemical Vapor Deposition segment is utilized for chemical Vapor deposition equipment manufacturing. The Stainless Design Concepts segment includes ultra-high purity manufacturing division in Saugerties, New York for gas control systems. The CVD Materials segment offers material coatings for aerospace, medical, electronic, and other application. The Corporate segment refers to the firm's administration activities. Its services include anti-corrosion, application lab, collaboration, customer support, printed electronics, fabricated quartzware, and process software. The firm serves the aerospace, glass coatings, medical, military, nanomaterials, optoelectronics, semiconductor, and solar photovoltaics markets. The company was founded by Leonard A. Rosenbaum on October 13, 1982 and is headquartered in Central Islip, NY. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
AFRICK ANDREW | 10% Owner | Dec 01 | Buy | 4.78 | 53,551 | 255,974 | 1,076,834 | Dec 01 08:26 PM | AFRICK ANDREW | 10% Owner | Nov 30 | Buy | 4.51 | 42,659 | 192,392 | 1,023,283 | Dec 01 08:26 PM | AFRICK ANDREW | 10% Owner | Nov 16 | Buy | 5.61 | 62,000 | 347,820 | 980,624 | Nov 17 01:59 PM | AFRICK ANDREW | 10% Owner | Nov 15 | Buy | 5.51 | 85,837 | 472,962 | 918,624 | Nov 17 01:59 PM | AFRICK ANDREW | 10% Owner | Aug 22 | Buy | 7.00 | 12,195 | 85,365 | 832,787 | Aug 23 04:00 PM |
|
|
|  |
 |
Market Cap | 141.38M | EPS (ttm) | -1.28 |
P/E | - | EPS this Y | 30.55% |
Forward P/E | - | EPS next Y | 8.20% |
PEG | - | EPS past 5Y | -55.84% |
P/S | 1.71 | EPS next 5Y | - |
P/B | 1.10 | EPS Q/Q | 42.28% |
Dividend | - | Sales Q/Q | 7.13% |
Insider Own | 42.92% | Inst Own | 36.96% |
Insider Trans | 4.94% | Inst Trans | -2.95% |
Short Float | 3.59% | Earnings | Nov 07/a |
Analyst Recom | 2.67 | Target Price | 2.58 |
Avg Volume | 480.65K | 52W Range | 1.04 - 15.30 |
|
|
|
Sight Sciences, Inc. is an ophthalmic medical device company, which focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment offers TearCare System and related components. The company was founded by Paul Badawi and David Y. Badawi in 2011 and is headquartered in Menlo Park, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Encrantz Staffan | Director | Nov 30 | Buy | 3.46 | 140,777 | 486,638 | 1,012,150 | Dec 01 07:39 PM | Encrantz Staffan | Director | Nov 29 | Buy | 3.50 | 3,223 | 11,280 | 871,373 | Dec 01 07:39 PM | Encrantz Staffan | Director | Nov 28 | Buy | 3.46 | 253,669 | 877,137 | 868,150 | Nov 28 08:32 PM | Encrantz Staffan | Director | Nov 27 | Buy | 3.31 | 246,331 | 815,947 | 614,481 | Nov 28 08:32 PM | Badawi David | Chief Technology Officer | Nov 24 | Option Exercise | 0.11 | 150,000 | 16,500 | 1,631,196 | Nov 28 08:16 PM |
|
|
 |
 |
Market Cap | 503.80M | EPS (ttm) | -0.92 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | 0.07% |
P/S | - | EPS next 5Y | - |
P/B | 9.66 | EPS Q/Q | 60.37% |
Dividend | - | Sales Q/Q | - |
Insider Own | 68.79% | Inst Own | 7.07% |
Insider Trans | 1.03% | Inst Trans | -15.53% |
Short Float | 13.70% | Earnings | Nov 13/b |
Analyst Recom | 3.00 | Target Price | 5.00 |
Avg Volume | 168.28K | 52W Range | 1.85 - 10.21 |
|
|
|
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
DUGGAN ROBERT W | Director | Nov 29 | Option Exercise | 5.95 | 1,667 | 9,919 | 36,392,861 | Dec 01 07:36 PM | DUGGAN ROBERT W | Director | Nov 29 | Buy | 9.44 | 158,600 | 1,497,184 | 36,551,461 | Dec 01 07:36 PM | DUGGAN ROBERT W | Director | Nov 29 | Buy | 9.21 | 60,000 | 552,600 | 60,000 | Dec 01 07:36 PM | DUGGAN ROBERT W | Director | Nov 28 | Buy | 8.98 | 124,397 | 1,117,085 | 36,391,194 | Nov 30 07:25 PM | DUGGAN ROBERT W | Director | Nov 17 | Buy | 6.10 | 20,241 | 123,470 | 36,266,797 | Nov 20 08:56 PM |
|
|
|  |
 |
Market Cap | 476.80M | EPS (ttm) | 0.16 |
P/E | 63.31 | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | 31.40 | EPS next 5Y | - |
P/B | 0.87 | EPS Q/Q | - |
Dividend | 4.34% | Sales Q/Q | 5.10% |
Insider Own | - | Inst Own | 25.79% |
Insider Trans | - | Inst Trans | - |
Short Float | 0.09% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 85.56K | 52W Range | 8.49 - 10.95 |
|
|
|
Invesco Trust for Investment Grade New York Municipals is a closed-ended fixed income mutual fund launched by Invesco Ltd. The fund is co-managed by Invesco Advisers, Inc., INVESCO Asset Management (Japan) Limited, INVESCO Asset Management Deutschland GmbH, INVESCO Asset Management Limited, Invesco Canada Ltd., Invesco Hong Kong Limited, and INVESCO Senior Secured Management, Inc. It invests in the fixed income markets of the United States. The fund primarily invests in investment grade New York municipal securities which include municipal bonds, municipal notes, municipal commercial paper, and lease obligations. It employs fundamental analysis with bottom-up security selection approach to create its portfolio. The fund was formerly known as Invesco Van Kampen Trust for Investment Grade New York Municipals. Invesco Trust for Investment Grade New York Municipals was formed on March 27, 1992 and is domiciled in the United States. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Saba Capital Management, L.P. | 10% Owner | Nov 30 | Buy | 9.98 | 83,498 | 833,310 | 2,479,585 | Dec 01 06:38 PM | Saba Capital Management, L.P. | 10% Owner | Nov 29 | Buy | 9.98 | 500 | 4,990 | 2,396,087 | Dec 01 06:38 PM | Saba Capital Management, L.P. | 10% Owner | Nov 28 | Buy | 9.89 | 45,026 | 445,307 | 2,395,587 | Nov 28 06:13 PM | Saba Capital Management, L.P. | 10% Owner | Nov 22 | Buy | 9.84 | 8,325 | 81,918 | 2,350,561 | Nov 24 06:35 PM | Saba Capital Management, L.P. | 10% Owner | Nov 21 | Buy | 9.78 | 3,600 | 35,208 | 2,342,236 | Nov 21 05:58 PM |
|
|
 |
 |
Market Cap | 234.01M | EPS (ttm) | -0.19 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | 12.71 | EPS next 5Y | - |
P/B | 0.87 | EPS Q/Q | - |
Dividend | 4.27% | Sales Q/Q | 3.60% |
Insider Own | - | Inst Own | 18.88% |
Insider Trans | - | Inst Trans | - |
Short Float | 0.15% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 58.20K | 52W Range | 8.58 - 10.58 |
|
|
|
Invesco Pennsylvania Value Municipal Income Trust is a closed-ended fixed income mutual fund launched by Invesco Ltd. The fund is co-managed by Invesco Advisers, Inc., INVESCO Asset Management (Japan) Limited, INVESCO Asset Management Deutschland GmbH, INVESCO Asset Management Limited, Invesco Canada Ltd., Invesco Hong Kong Limited, and INVESCO Senior Secured Management, Inc. It invests in the fixed income markets of the United States. The fund primarily invests in investment grade Pennsylvania municipal securities which include municipal bonds, municipal notes, municipal commercial paper, and lease obligations. It employs fundamental analysis with bottom-up security selection approach to create its portfolio. The fund was formerly known as Invesco Van Kampen Pennsylvania Value Municipal Income Trust. Invesco Pennsylvania Value Municipal Income Trust was formed on April 30, 1993 and is domiciled in the United States. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Saba Capital Management, L.P. | 10% Owner | Nov 30 | Buy | 9.63 | 2,397 | 23,083 | 2,507,203 | Dec 01 06:36 PM | Saba Capital Management, L.P. | 10% Owner | Nov 28 | Buy | 9.48 | 74,537 | 706,611 | 2,504,806 | Nov 28 06:12 PM | Saba Capital Management, L.P. | 10% Owner | Nov 27 | Buy | 9.49 | 22,064 | 209,387 | 2,430,269 | Nov 28 06:12 PM |
|
|
|  |
 |
Market Cap | 477.02M | EPS (ttm) | -1.57 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | 13.21 | EPS next 5Y | - |
P/B | 0.87 | EPS Q/Q | - |
Dividend | 3.35% | Sales Q/Q | -3.10% |
Insider Own | - | Inst Own | 19.75% |
Insider Trans | - | Inst Trans | - |
Short Float | 0.11% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 104.35K | 52W Range | 10.06 - 12.20 |
|
|
|
Nuveen New Jersey Quality Municipal Income Fund is a closed ended fixed income mutual fund launched by Nuveen Investments, Inc. The fund is co-managed by Nuveen Fund Advisors LLC and Nuveen Asset Management, LLC. It invests in the fixed income markets of New Jersey. The fund invests in undervalued municipal securities and other related investments that are, exempt from regular federal and New Jersey income taxes that are rated Baa or BBB or better. It employs fundamental analysis with bottom-up stock picking approach to create its portfolio. The fund benchmarks the performance of its portfolio against the Standard & Poor's (S&P) New Jersey Municipal Bond Index. The fund was formerly known as Nuveen New Jersey Dividend Advantage Municipal Fund. Nuveen New Jersey Quality Municipal Income Fund was formed on June 1, 1999 and is domiciled in the United States. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Saba Capital Management, L.P. | 10% Owner | Nov 30 | Buy | 11.51 | 46,424 | 534,340 | 5,261,856 | Dec 01 06:35 PM | Saba Capital Management, L.P. | 10% Owner | Nov 29 | Buy | 11.48 | 40,888 | 469,394 | 5,215,432 | Dec 01 06:35 PM | Saba Capital Management, L.P. | 10% Owner | Nov 28 | Buy | 11.38 | 111,540 | 1,269,325 | 5,174,544 | Nov 28 06:10 PM | Saba Capital Management, L.P. | 10% Owner | Nov 27 | Buy | 11.32 | 11,779 | 133,338 | 5,063,004 | Nov 28 06:10 PM | Saba Capital Management, L.P. | 10% Owner | Nov 21 | Buy | 11.19 | 101,956 | 1,140,888 | 5,051,225 | Nov 21 05:56 PM |
|
|
 |
 |
Market Cap | 415.03M | EPS (ttm) | -1.72 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | 13.51 | EPS next 5Y | - |
P/B | 0.85 | EPS Q/Q | - |
Dividend | 3.22% | Sales Q/Q | 1.20% |
Insider Own | - | Inst Own | 22.99% |
Insider Trans | - | Inst Trans | - |
Short Float | 0.09% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 73.83K | 52W Range | 9.65 - 12.01 |
|
|
|
Nuveen Pennsylvania Quality Municipal Income Fund is a closed ended fixed income mutual fund launched by Nuveen Investments, Inc. The fund is co-managed by Nuveen Fund Advisors LLC and Nuveen Asset Management, LLC. It invests in the fixed income markets of Pennsylvania. The fund invests in tax exempt municipal bonds, with a rating of Baa/BBB or higher. It employs fundamental analysis, with bottom-up stock picking approach, to create its portfolio. The fund benchmarks the performance of its portfolio against the Standard & Poor's Pennsylvania Municipal Bond Index and Standard & Poor's National Municipal Bond Index. The fund was formerly known a Nuveen Pennsylvania Investment Quality Municipal Fund. Nuveen Pennsylvania Quality Municipal Income Fund was formed on December 20, 1990 and is domiciled in the United States. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Saba Capital Management, L.P. | 10% Owner | Nov 29 | Buy | 10.98 | 28,424 | 312,096 | 4,304,522 | Dec 01 06:33 PM | Saba Capital Management, L.P. | 10% Owner | Nov 28 | Buy | 10.93 | 50,625 | 553,331 | 4,276,098 | Nov 28 06:08 PM | Saba Capital Management, L.P. | 10% Owner | Nov 27 | Buy | 10.89 | 33,162 | 361,134 | 4,225,473 | Nov 28 06:08 PM | Saba Capital Management, L.P. | 10% Owner | Nov 21 | Buy | 10.80 | 6,520 | 70,416 | 4,192,311 | Nov 21 05:51 PM | Saba Capital Management, L.P. | 10% Owner | Nov 20 | Buy | 10.72 | 10,287 | 110,277 | 4,185,791 | Nov 21 05:51 PM |
|
|
 |
 |
Market Cap | 396.76M | EPS (ttm) | 0.64 |
P/E | 18.55 | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | - | EPS Q/Q | - |
Dividend | 10.53% | Sales Q/Q | - |
Insider Own | - | Inst Own | 26.80% |
Insider Trans | - | Inst Trans | - |
Short Float | 0.18% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 76.31K | 52W Range | 10.60 - 13.02 |
|
|
The Fund's investment objective is to provide attractive total return through high current income and capital appreciation. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment strategy uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund may invest in equity and debt securities of any type without limit. The relative allocations of the Fund's managed assets for investment between equity and debt securities, and relative allocations to the different types of equity and income strategies, will vary from time to time, consistent with the Fund's investment objective. The Fund uses leverage. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Saba Capital Management, L.P. | 10% Owner | Nov 30 | Buy | 11.65 | 1,651 | 19,234 | 4,717,729 | Dec 01 06:31 PM | Saba Capital Management, L.P. | 10% Owner | Nov 29 | Buy | 11.68 | 7,607 | 88,850 | 4,716,078 | Dec 01 06:31 PM | Saba Capital Management, L.P. | 10% Owner | Nov 27 | Buy | 11.53 | 13,150 | 151,620 | 4,708,471 | Nov 28 06:06 PM | Saba Capital Management, L.P. | 10% Owner | Nov 24 | Buy | 11.52 | 600 | 6,912 | 4,695,321 | Nov 24 06:33 PM | Saba Capital Management, L.P. | 10% Owner | Nov 22 | Buy | 11.59 | 5,216 | 60,453 | 4,694,721 | Nov 24 06:33 PM |
|
|
|